Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)

Objective Antipsychotic‐induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First‐episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients. Method Data were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as outcomes. Results Four weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P